What's fueling the biotech engine—2012 to 2013

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

(2013)   BLOOD

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

(2013) Cem Gabay et al.   LANCET

Failure to launch

(2013)   NATURE BIOTECHNOLOGY

Building a wall against biosimilars

(2013)   NATURE BIOTECHNOLOGY

Biosimilars legislation state by state

(2013)   NATURE BIOTECHNOLOGY

Anthrax drug first antibacterial mAb to win approval

(2013) Jeffrey L Fox   NATURE BIOTECHNOLOGY

What's fueling the biotech engine—2011 to 2012

(2012) Saurabh Aggarwal   NATURE BIOTECHNOLOGY

What's fueling the biotech engine—2010 to 2011

(2011) Saurabh Aggarwal   NATURE BIOTECHNOLOGY

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

(2010) Richard E Pratley et al.   LANCET

What's fueling the biotech engine—2009–2010

(2010) Saurabh Aggarwal   NATURE BIOTECHNOLOGY

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE

What's fueling the biotech engine—2008

(2009) Saurabh Aggarwal   NATURE BIOTECHNOLOGY

What's fueling the biotech engine—2007

(2008) Saurabh Aggarwal   NATURE BIOTECHNOLOGY